Veracyte Inc reports results for the quarter ended September 30 - Earnings Summary

• Veracyte Inc VCYT.OQ reported quarterly adjusted earnings of 51 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 6 cents. The mean expectation of thirteen analysts for the quarter was for earnings of 22 cents per share. Wall Street expected results

• Revenue rose 11.2% to $131.87 million from a year ago; analysts expected $125.15 million.

• Veracyte Inc's reported EPS for the quarter was 24 cents​.

• The company reported quarterly net income of $41.15 million.

• Veracyte Inc shares had fallen by 15.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Veracyte Inc is $50.00, about 28.6% above its last closing price of $35.72

This summary was machine generated from LSEG data February 25 at 11:24 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)